C07D211/18

PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF
20180170862 · 2018-06-21 ·

Small molecule compounds derived from -sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF
20180170862 · 2018-06-21 ·

Small molecule compounds derived from -sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.

Synthetic process
09981957 · 2018-05-29 · ·

The present invention relates to a process for preparing substituted piperidine compounds and especially chiral substituted piperidine compounds. The process involves reacting a substituted pyridinium ion with an amine as defined herein, in the presence of a hydrogen donor, a catalysts and a suitable solvent.

Synthetic process
09981957 · 2018-05-29 · ·

The present invention relates to a process for preparing substituted piperidine compounds and especially chiral substituted piperidine compounds. The process involves reacting a substituted pyridinium ion with an amine as defined herein, in the presence of a hydrogen donor, a catalysts and a suitable solvent.

SUBSTITUTED POLYFLUORENE COMPOUNDS
20240360319 · 2024-10-31 ·

The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.

SUBSTITUTED POLYFLUORENE COMPOUNDS
20240360319 · 2024-10-31 ·

The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.

Liquid crystal composition and liquid crystal display device

The liquid crystal composition contains a compound contributing to high stability to heat or ultraviolet light, has negative dielectric anisotropy and has a nematic phase, and may contain a specific compound having high negative dielectric anisotropy as a first component, a specific compound having a high maximum temperature or small viscosity as a second component, and a specific compound having a polymerizable group.

Liquid crystal composition and liquid crystal display device

The liquid crystal composition contains a compound contributing to high stability to heat or ultraviolet light, has negative dielectric anisotropy and has a nematic phase, and may contain a specific compound having high negative dielectric anisotropy as a first component, a specific compound having a high maximum temperature or small viscosity as a second component, and a specific compound having a polymerizable group.